Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876612 | PMC |
| http://dx.doi.org/10.1016/j.celrep.2022.111883 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IGF1 drives Wnt-induced joint damage and is a potential therapeutic target for osteoarthritis.
Nat Commun
October 2024
Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Osteoarthritis is the most common joint disease and a global leading cause of pain and disability. Current treatment is limited to symptom relief, yet there is no disease-modifying therapy. Its multifactorial etiology includes excessive activation of Wnt signaling, but how Wnt causes joint destruction remains poorly understood.
View Article and Find Full Text PDFThe clinical and genetic aspects of six individuals with variants and isolated growth hormone deficiency type II.
Front Endocrinol (Lausanne)
October 2024
Department of Endocrinology, Genetics and Metabolism, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, Fujian, ;China.
Article Synopsis
- Isolated growth hormone deficiency type II (IGHD II) is a genetic condition leading to low growth hormone production, resulting in stunted growth and lower IGF-1 levels in affected individuals.
- The study examined six children from Chinese families with IGHD II, revealing various genetic variants associated with the condition, including several novel mutations.
- After starting growth hormone replacement therapy, the children showed significant improvement in height, with an average increase of 1.21 SDS in the first six months and 1.79 SDS in the first year of treatment.
Characterization of Primary IGF-1 Deficiency in a Cohort of Canadian Children with Short Stature Using a Novel Algorithm Tailored to Electronic Medical Records.
Children (Basel)
June 2024
Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.
Article Synopsis
- Severe primary insulin-like growth factor-I deficiency (SPIGFD) is a rare disorder that leads to short stature in children due to low IGF-1 levels, and it may often go undiagnosed.* -
- A study was conducted at a pediatric care center using an electronic medical record (EMR) algorithm to find children with short stature and low IGF-1 levels, identifying 30 potential cases of SPIGFD.* -
- Ultimately, none of these identified patients had SPIGFD, demonstrating that the EMR algorithm can help identify children who might benefit from treatment and can be applied to other rare diseases.*
Common and Uncommon Mouse Models of Growth Hormone Deficiency.
Endocr Rev
November 2024
Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA.
Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the 5 "common" mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased adiposity, and enhanced insulin sensitivity.
View Article and Find Full Text PDFEvolving growth hormone deficiency: proof of concept.
Front Endocrinol (Lausanne)
May 2024
Division of Pediatric Endocrinology and Diabetes, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Introduction: We present the evolution of GHD in adolescent males with persistent growth failure, in whom the diagnosis was established after a second GH stimulation test (GST).
Methods: We performed a retrospective chart review of children who presented for short stature (height less < 2SD for mean/mid-parental height) and/or growth failure (sustained growth velocity < 0 SD) to pediatric endocrinology at Mount Sinai Kravis Children's Hospital, New York and who had 2 GSTs. Data collected from electronic medical records were analyzed using SPSS v28.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!